Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment Source: Annual Congress 2009 - Pulmonary infections Year: 2009
The efficiency of moxifloxacin (MOX) in community-acquired pneumonias (CAP) treatment while the initial antibacterial therapy (IAT) was inefficient Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005
Lower overall healthcare costs with telithromycin (TEL) versus clarithromycin (CLA) in community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 152s Year: 2003
Fluoroquinolone versus β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008
Meta analysis of hospitalized patients with community-acquired pneumonia (CAP) treated with levofloxacin Source: Eur Respir J 2004; 24: Suppl. 48, 188s Year: 2004
One year analysis of hospital-treated, community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 356s Year: 2002
Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients Source: Annual Congress 2011 - COPD management Year: 2011
Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005
Legionella pneumonia in patients hospitalized with community-acquired pneumonia (CAP) in NorwaySource: Annual Congress 2012 - Management of severe respiratory infections Year: 2012
Mortality directly related to community-acquired pneumonia (CAP) in hospitalized patients: results from the community-acquired pneumonia organization (CAPO) international cohort study Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007
Impact of age and gender on efficacy and safety of omadacycline (OMC) vs. moxifloxacin (MOX) in community-acquired bacterial pneumonia (CABP) Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018
Are there radiographic differences between patients with community-acquired (CAP) and healthcare-associated pneumonias (HCAP)? Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients Year: 2010
Earlier discharge of patients treated with moxifloxacin IV/PO monotherapy (MXF) versus amoxicillin/clavulanate (AMC) ±] clarithromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare Source: Eur Respir J 2002; 20: Suppl. 38, 561s Year: 2002
Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006
Determinants of performance of indicators on antibiotic use in community-acquired pneumonia (CAP) at hospitals Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005
Relevance of correct antibiotic choice in community-acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005
Antibacterial activity of telithromycin (TEL) and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in the PROTEKT study 1999–2002 Source: Eur Respir J 2004; 24: Suppl. 48, 186s Year: 2004
Clinical stability in patients with community- acquired pneumonia (CAP) Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections Year: 2011
Change in the susceptibility pattern of Streptococcus pneumoniae (SP) and risk factors (RF) for antibiotic resistance (AR) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 546s Year: 2003
Use of ceftriaxone/sulbactame for treatment of mild-to-severe community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment of airways disease Year: 2009